VX-121/TEZ/D-IVA
Sponsors
Vertex Pharmaceuticals Incorporated
Conditions
Cystic Fibrosis
Phase 1
Pharmacokinetics and Safety Assessment of VX-121/Tezacaftor/Deutivacaftor in Participants With Moderate Hepatic Impairment
CompletedNCT05437120
Start: 2022-07-22End: 2023-03-16Updated: 2023-03-30
A Study to Evaluate the Relative Bioavailability of a Fixed-dose Combination Tablet of VX-121/Tezacaftor/Deutivacaftor
CompletedNCT05535959
Start: 2022-09-15End: 2022-11-09Updated: 2022-12-12
Phase 3
A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)
CompletedNCT05033080
Start: 2021-09-14End: 2023-11-21Updated: 2024-10-03
A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation
CompletedNCT05076149
Start: 2021-10-27End: 2023-11-30Updated: 2024-06-13
Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age
Active, not recruitingNCT05422222
Start: 2022-06-21End: 2030-06-30Target: 210Updated: 2026-05-28
A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy
Active, not recruitingNCT05444257
Start: 2022-11-08End: 2026-10-30Updated: 2026-09-10